Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma

Peripheral T-cell lymphomas (PTCLs) are associated with poor prognosis when treated with cytotoxic chemotherapy. We report the findings of a phase 2 study evaluating a chemotherapy-free combination of romidepsin plus lenalidomide as initial treatment for patients with PTCL who were aged >60 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Jia, Zain, Jasmine, Palmer, Brett, Jovanovic, Borko, Mi, Xinlei, Swaroop, Alok, Winter, Jane N., Gordon, Leo I., Karmali, Reem, Moreira, Jonathan, Petrich, Adam M., Pro, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561000/
https://www.ncbi.nlm.nih.gov/pubmed/37327113
http://dx.doi.org/10.1182/bloodadvances.2023009767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561000/
https://www.ncbi.nlm.nih.gov/pubmed/37327113
http://dx.doi.org/10.1182/bloodadvances.2023009767

Ejemplares similares